Furthermore, the results of flow cytometry and qRT-PCR analysis of the M2 and M1 markers, and ELISA analyses of the IL10 and IL6 cytokines revealed that BMDMs failed to switch to the M2 phenotype in the knockdown group following SCLC-derived exosome treatment (Fig. 5F–H). This evidence concerns the gene IL10 and small cell lung carcinoma.